• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在考虑患者入组不均匀、失访、不依从和分层的情况下,对生存分析的样本量和检验效能进行评估。

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification.

作者信息

Lachin J M, Foulkes M A

出版信息

Biometrics. 1986 Sep;42(3):507-19.

PMID:3567285
Abstract

When designing a clinical trial to test the equality of survival distributions for two treatment groups, the usual assumptions are exponential survival, uniform patient entry, full compliance, and censoring only administratively at the end of the trial. Various authors have presented methods for estimation of sample size or power under these assumptions, some of which allow for an R-year accrual period with T total years of study, T greater than R. The method of Lachin (1981, Controlled Clinical Trials 2, 93-113) is extended to allow for cases where patients enter the trial in a nonuniform manner over time, patients may exit from the trial due to loss to follow-up (other than administrative), other patients may continue follow-up although failing to comply with the treatment regimen, and a stratified analysis may be planned according to one or more prognostic covariates.

摘要

在设计一项临床试验以检验两个治疗组生存分布的相等性时,通常的假设是指数生存、患者均匀入组、完全依从以及仅在试验结束时进行管理性删失。许多作者已经提出了在这些假设下估计样本量或检验效能的方法,其中一些方法允许有一个R年的入组期,总研究时间为T年,T大于R。拉钦(1981年,《对照临床试验》2,93 - 113)的方法得到了扩展,以适用于患者随时间非均匀入组、患者可能因失访(而非管理性原因)退出试验、其他患者尽管未遵守治疗方案仍继续随访的情况,并且可以根据一个或多个预后协变量计划进行分层分析。

相似文献

1
Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification.在考虑患者入组不均匀、失访、不依从和分层的情况下,对生存分析的样本量和检验效能进行评估。
Biometrics. 1986 Sep;42(3):507-19.
2
Sample size determination for comparing several survival curves with unequal allocations.用于比较几个不等分配的生存曲线的样本量确定。
Stat Med. 2004 Jun 15;23(11):1793-815. doi: 10.1002/sim.1771.
3
Sample size calculation for the weighted rank statistics with paired survival data.配对生存数据加权秩统计量的样本量计算。
Stat Med. 2008 Jul 30;27(17):3350-65. doi: 10.1002/sim.3189.
4
A simple method for calculating power based on a prior trial.基于前期试验的一种计算功效的简单方法。
J Clin Epidemiol. 2010 Sep;63(9):992-7. doi: 10.1016/j.jclinepi.2009.10.011. Epub 2010 Jun 22.
5
Variance estimation in clinical studies with interim sample size re-estimation.在进行中期样本量重新估计的临床研究中的方差估计。
Biometrics. 2005 Jun;61(2):355-61. doi: 10.1111/j.1541-0420.2005.00315.x.
6
Calculation of sample size in survival trials: the impact of informative noncompliance.生存试验中样本量的计算:信息性不依从的影响
Biometrics. 2004 Sep;60(3):800-6. doi: 10.1111/j.0006-341X.2004.00231.x.
7
Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.考虑不依从与结局事件风险之间随时间变化关系的生存试验中的样本量计算。
Clin Trials. 2006;3(4):349-59. doi: 10.1177/1740774506069155.
8
Sample size determination in clinical trials with an emphasis on exponentially distributed responses.侧重于指数分布响应的临床试验中的样本量确定。
Biometrics. 1987 Dec;43(4):875-83.
9
Nonparametric estimation of duration of accrual and total study length for clinical trials.临床试验中累积期和总研究时长的非参数估计
Biometrics. 1987 Dec;43(4):903-12.
10
Interim analyses in 2 x 2 crossover trials.2×2交叉试验中的期中分析。
Biometrics. 1995 Sep;51(3):932-45.

引用本文的文献

1
Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial.在肝细胞癌患者中,将树突状细胞疫苗接种添加到预处理环磷酰胺和化疗栓塞中:免疫TACE试验。
Clin Cancer Res. 2025 Aug 14;31(16):3412-3423. doi: 10.1158/1078-0432.CCR-25-0142.
2
Simulations-Based Least Required Sample Size and Power in Clinical Trials with Time-to-Event endpoint and Variable Hazard.基于模拟的具有事件发生时间终点和可变风险的临床试验中所需的最小样本量和检验效能
Int J Epidemiol Public Health Res. 2024;5(3). Epub 2024 Sep 20.
3
Optimizing Post-activation Performance Enhancement in Athletic Tasks: A Systematic Review with Meta-analysis for Prescription Variables and Research Methods.
优化运动任务中的激活后性能增强:对处方变量和研究方法进行荟萃分析的系统评价
Sports Med. 2025 Apr;55(4):977-1008. doi: 10.1007/s40279-024-02170-6. Epub 2025 Jan 24.
4
Paclitaxel- or sirolimus-coated balloons used for ArterioVEnous fistulas-2 (PAVE-2): study protocol for a randomised controlled trial to determine the efficacy of paclitaxel- or sirolimus-coated balloons in arteriovenous fistulas used for haemodialysis.紫杉醇或西罗莫司涂层球囊在动静脉瘘中的应用-2(PAVE-2):一项随机对照试验研究方案,旨在确定紫杉醇或西罗莫司涂层球囊在用于血液透析的动静脉瘘中的疗效。
Trials. 2024 Oct 31;25(1):734. doi: 10.1186/s13063-024-08502-1.
5
Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting.在具有事件发生时间终点的随机非劣效性试验设计中,使用比例的非劣效性检验,重点关注低事件率情况。
Clin Trials. 2025 Apr;22(2):131-141. doi: 10.1177/17407745241284786. Epub 2024 Oct 12.
6
History of the Diabetes Control and Complications Trial and Its Follow-up Epidemiology of Diabetes Interventions and Complications Study: Studies That Changed the Treatment of Type 1 Diabetes.糖尿病控制与并发症试验及其后续的糖尿病干预与并发症流行病学研究的历史:改变1型糖尿病治疗方式的研究
Diabetes Care. 2024 Sep 1;47(9):1511-1517. doi: 10.2337/dci24-0063.
7
Designing a phase-III time-to-event clinical trial using a modified sample size formula and Poisson-Gamma model for subject accrual that accounts for the lag in site initiation using the PERT distribution.使用修改后的样本量公式和泊松-伽马模型设计 III 期生存时间临床试验,该模型考虑了使用 PERT 分布对站点启动的滞后,以进行受试者入组。
Stat Med. 2023 Dec 30;42(30):5694-5707. doi: 10.1002/sim.9935. Epub 2023 Nov 5.
8
RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia.甲磺酸萘莫司他(一种强效跨膜丝氨酸蛋白酶2(TMPRSS2)抑制剂)用于新冠肺炎患者的随机临床试验
J Clin Med. 2023 Oct 19;12(20):6618. doi: 10.3390/jcm12206618.
9
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.纳武利尤单抗联合伊匹单抗治疗复发性或难治性不明原发癌:一项 II 期试验。
Nat Commun. 2023 Oct 24;14(1):6761. doi: 10.1038/s41467-023-42400-5.
10
Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach.随机临床试验中具有非比例风险的无效监测:最优条件功效方法。
Clin Trials. 2023 Dec;20(6):603-612. doi: 10.1177/17407745231181908. Epub 2023 Jun 27.